Recent advances in developing vaccines against Toxoplasma gondii: an update

被引：45

作者：

Zhang, Nian-Zhang ^{[1
]}

Wang, Meng ^{[1
]}

Xu, Ying ^{[1
,2
]}

Petersen, Eskild ^{[3
]}

Zhu, Xing-Quan ^{[1
]}

机构：

[1] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, Key Lab Vet Parasitol Gansu Prov, State Key Lab Vet Etiol Biol, Lanzhou, Peoples R China

[2] China Agr Univ, Coll Vet Med, Natl Anim Protozoa Lab, Key Lab Anim Epidemiol & Zoonosis,Minist Agr, Beijing 100094, Peoples R China

[3] Aarhus Univ, Fac Hlth Sci, Inst Clin, Dept Infect Dis, Aarhus, Denmark

来源：

EXPERT REVIEW OF VACCINES | 2015年 / 14卷 / 12期

基金：

中国国家自然科学基金;

关键词：

adjuvant; delivery system; Toxoplasma gondii; toxoplasmosis; vaccines; vaccine candidates; EXCRETORY-SECRETORY ANTIGENS; LASTING PROTECTIVE IMMUNITY; DNA VACCINE; BALB/C MICE; IFN-GAMMA; INTRANASAL IMMUNIZATION; SEQUENCE VARIATION; RHOPTRY PROTEINS; CYCLOPHILIN GENE; HOST-RESISTANCE;

D O I：

10.1586/14760584.2015.1098539

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Toxoplasma gondii, a significant public health risk, is able to infect almost all warm-blooded animals including humans, and it results in economic losses in production animals. In the last three years, a large number of vaccination experiments have been performed to control T. gondii infection, with the target of limiting the acute infection and reducing or eliminating tissue cysts in the intermediate hosts. In this paper, we summarize the latest results of the veterinary vaccines against T. gondii infection since 2013. Immunization with live-attenuated whole organisms of non-reverting mutants has been shown to induce remarkably potent immune responses associated with control of acute and chronic toxoplasmosis. The non-cyst-forming mutants are promising new tools for the development of veterinary vaccines against T. gondii infection.

引用

页码：1609 / 1621

页数：13

共 50 条

[21] Advances in understanding immunity to Toxoplasma gondii
Tait, Elia D.
Hunter, Christopher A.
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2009, 104 (02): : 201 - 210
[22] Moving towards improved vaccines for Toxoplasma gondii
Li, Yawen
Zhou, Huaiyu
EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (03) : 273 - 280
[23] Toxoplasma gondii-Current drugs and future vaccines against an underestimated protozoan infection
Borkens, Yannick
INTERNIST, 2021, 62 (10): : 1123 - 1132
[24] Advances in Designing and Developing Vaccines Against Zika Virus
Munjal, Ashok
Khandia, Rekha
Tiwari, Ruchi
Chakraborty, Sandip
Karthik, Kumaragurubaran
Dhama, Kuldeep
INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2017, 13 (07) : 667 - 676
[25] Vaccines against Toxoplasma gondii: challenges and opportunities (vol 104, pg 252, 2009)
Jongert, Erik
Roberts, Craig W.
Gargano, Nicola
Foerster-Waldl, Elisabeth
Petersen, Eskild
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2010, 105 (01):
[26] Development of multiepitope subunit protein vaccines against Toxoplasma gondii using an immunoinformatics approach
Onile, Olugbenga S.
Ojo, Glory J.
Oyeyemi, Bolaji Fatai
Agbowuro, Gbenga O.
Fadahunsi, Adeyinka, I
NAR GENOMICS AND BIOINFORMATICS, 2020, 2 (03)
[27] Vaccines against seasonal and avian influenza: Recent advances
Osterhaus, Albert D. M. E.
Poland, Gregory A.
VACCINE, 2008, 26 : D1 - D2
[28] Recent advances in vaccines against viral haemorrhagic fevers
Baize, S
Marianneau, P
Georges-Courbot, MC
Deubel, V
CURRENT OPINION IN INFECTIOUS DISEASES, 2001, 14 (05) : 513 - 518
[29] Vaccination concepts against Toxoplasma gondii
Garcia, Joao Luis
EXPERT REVIEW OF VACCINES, 2009, 8 (02) : 215 - 225
[30] Trovafloxacin is active against Toxoplasma gondii
Khan, AA
Slifer, T
Araujo, FG
Remington, JS
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) : 1855 - 1859

← 1 2 3 4 5 →